NIPT
Early IDENTIFY Trial Results Suggest Half of Women With Non-Reportable NIPT Result Have Cancer
At the American College of Medical Genetics and Genomics annual meeting, NICHD Director Diana Bianchi reported that whole-body MRI was the best follow-up test to confirm or rule out cancer.
The company is planning to launch a 4-in-1 prenatal screening test, a liquid biopsy test, and a minimal residual disease assay in the coming year.
The technique, used in noninvasive prenatal testing to detect microduplications or microdeletions, could detect copy number alterations in B-cell lymphoma patients.
Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year
Premium
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.